132414-59-6

Basic information

• Product Name: 5-Methyl-1H-hexahydropyrrolo[3,4-b]pyrrole
• Synonyms: 5-Methyl-1H-hexahydropyrrolo[3,4-b]pyrrole;5-methyl-2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[2,3-c]pyrrole;5-methyl-octahydropyrrolo[2,3-c]pyrrole
• CAS NO: 132414-59-6
• Molecular Formula: C7H12N2
• Molecular Weight: 124.186
• Mol File: 132414-59-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 169.626°C at 760 mmHg
• Flash Point: 62.735°C
• Appearance: /
• Density: 0.97g/cm³
• Vapor Pressure: 1.528mmHg at 25°C
• Refractive Index: 1.486
• CAS DataBase Reference: 5-Methyl-1H-hexahydropyrrolo[3,4-b]pyrrole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methyl-1H-hexahydropyrrolo[3,4-b]pyrrole(132414-59-6)
• EPA Substance Registry System: 5-Methyl-1H-hexahydropyrrolo[3,4-b]pyrrole(132414-59-6)

Safety Data

• Hazardous Substances Data: 132414-59-6(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 132414-59-6 differently. You can refer to the following data:
1. 5-METHYLOCTAHYDROPYRROLO[3,4-B]PYRROLE (cas# 132414-59-6) is a useful research chemical.
2. 5-Methyl-1H-hexahydropyrrolo[3,4-b]pyrrole can be used as organic synthesis intermediate and pharmaceutical intermediate, mainly used in laboratory research and development process and chemical production process.

InChI:InChI=1/C7H14N2/c1-9-4-6-2-3-8-7(6)5-9/h6-8H,2-5H2,1H3

Upstream product

• 180975-51-3 cis-tert-butyl hexahydropyrrolo[2,3-c]pyrrole-5(1H)-carboxylate 
• 180975-51-3 cis-tert-butyl 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-b]pyrrole-5-carboxylate 
• 370880-09-4 (3aR,6aR)-octahydro-pyrrolo[3,4-b]pyrrole-1-carboxylic acid tert-butyl ester 
• 128740-02-3 ethyl N-(2,2-dimethoxyethyl)-N-(prop-2-en-1-yl)carbamate 
• 128740-03-4 N-allyl-N-(2-oxoethyl)carbamic acid,ethyl ester 
• 370879-99-5 ethyl (3aR,6aR)-1-[(1R)-1-phenylethyl]-2,3,3a,4,6,6a-hexahydro-pyrrolo[3,2-c]pyrrole-5-carboxylate 
• 370880-03-8 (3aR,6aR)-1-[(1R)-1-phenylethyl]-3,3a,4,5,6,6a-hexahydro-2H-pyrrolo[3,2-c]pyrrole 
• 1421372-15-7 (3aR,6aR)-5-methyl-1-[(1R)-1-phenylethyl]-2,3,3a,4,6,6a-hexahydropyrrolo[3,2-c]pyrrole 
• 948846-60-4 (3aR,6aR)-5-methyl-octahydro-pyrrolo[3,4-b]pyrrole-1-carboxylic acid tert-butyl ester 
• 132414-95-0 2-benzyl-7-methyl-2,7-diazabicyclo[3.3.0]octane 

Downstream Products

• 948846-75-1 (3aR,6aR)-5-methyl-1-(4-piperazin-1-yl-phenyl)-octahydro-pyrrolo[3,4-b]pyrrole 
• 948846-22-8 2-{5-[4-((3aR,6aR)-5-methyl-octahydro-pyrrolo[3,4-b]pyrrol-1-yl)-phenyl]-pyridin-2-yl}-2H-pyridazin-3-one 
• 948846-79-5 (3aR,6aR)-5-methyl-1-(4-(4,4,5,5-tetramethyl-1,3-dioxaborolan-2-yl)-phenyl)-octahydro-pyrrolo[3,4-b]pyrrole 

Relevant articles and documents

SUBSTITUTED PYRIDOINDOLES FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION

The present invention relates to novel compounds of formula (I) or (II), (I) or (II), wherein R1 to R6, R11 to R17 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.

2 - (2, 4, 5 - SUBSTITUTED -ANILINO) PYRIMIDINE DERIVATIVES AS EGFR MODULATORS USEFUL FOR TREATING CANCER

The present invention relates to certain 2-(2,4,5-substituted-anilino) pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exonl9 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.

Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships

A new histamine H3 receptor (H3R) antagonist chemotype 1 was designed by combining key pharmacophoric elements from two different precursor structural series and then simplifying and optimizing the resulting combined structural featu